Finerenone 10 mg Tablet (LuciFine) is an oral medicine prescribed to patients with chronic kidney disease associated with cardiovascular risks. It can also be indicated among individuals with similar health complications amidst Type-2 Diabetes (T2D). Finerenone received FDA approval in 2021.
This medication is primarily recommended as an adjunct therapy to manage underlying symptoms effectively. If the patient experiences any adverse effects or shows intolerance, the medication may be discontinued. The treatment regimen varies among patients, and this medication must be taken only under medical guidance.
Finerenone 10 mg Tablet (LuciFine)
This first-line treatment is indicated for the following purposes:
By minimizing the risk of such long-term health issues, this drug prevents death due to cardiovascular events and helps in avoiding hospitalization, too.
- Lowering the risk of severe kidney diseases
- Management of heart health issues linked to poor kidney conditions
- Prevention of chronic health issues associated with kidney disorders

















